Company Overview

Zoetis Inc. stands as the world's leading animal health company, dedicated to nurturing our world and humankind by advancing care for animals. Founded in 1950 and headquartered in Parsippany, New Jersey, Zoetis is the largest global producer of medicines and vaccines for both companion animals and livestock. The company operates in over 100 countries across North America, Europe, and internationally.

With over 70 years of experience, Zoetis focuses on discovering, developing, manufacturing, and commercializing a wide range of animal health solutions. They provide veterinarians, livestock producers, and pet owners with essential medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products, supporting those who care for animals worldwide.

Business Operations and Market Segments

Zoetis Inc. operates globally, engaging in the discovery, development, manufacture, and commercialization of animal health products. Their offerings include medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions.

The company's product portfolio is comprehensive, catering to diverse needs:

- Core Products: Including parasiticides, vaccines, dermatology treatments, anti-infectives, pain and sedation medications, and other pharmaceuticals.

- Diagnostic Solutions: Encompassing point-of-care diagnostic products, instruments, reagents, rapid immunoassay tests, reference laboratory services, and blood glucose monitors.

- Other Products: Covering nutritionals, biodevices, genetic tests, and precision animal health technologies.

Zoetis commercializes its products across two primary species categories:

- Livestock: Including cattle, swine, poultry, fish, and sheep. This segment accounts for approximately 35% of total revenue.

- Companion Animals: Including dogs, cats, and horses. This segment contributes nearly 65% of total revenue, showcasing strong demand for pet health products.

The company operates through two geographical segments: the United States (U.S.) and International.

Financial Performance and Market Position

Market Position

As of September 2025, Zoetis holds a dominant position in the global animal health market with a market capitalization of $75.4 billion. The trailing twelve-month revenue stands at $9.4 billion, underscoring its significant scale and market leadership.

Recent Financial Results

- Q3 2025 Performance:

- Revenue grew robustly by 11% year-on-year to $2.4 billion.

- The U.S. segment reported an impressive 15% revenue growth, reaching $1.3 billion, primarily driven by strong companion animal product demand.

- Livestock product sales also saw growth, with the international segment increasing by 7% on a reported basis and 15% operationally.

- Profitability showed strong improvement, with adjusted net income rising 13.8% year-over-year to $716 million. Adjusted EPS was $1.58, exceeding analysts' estimates by 8.2%.

- Q2 2025 Performance:

- Adjusted earnings per share (EPS) reported at $1.76, up from $1.56 in the prior year, surpassing the consensus estimate of $1.61.

- Full Year 2024 Performance:

- Reported revenue of $2.3 billion, a 5% increase.

- Net income was $581 million, or $1.29 per diluted share, marking an 11% and 13% increase, respectively, on a reported basis for the fourth quarter of 2024.

Growth Outlook

For fiscal year 2025, Zoetis's earnings are projected to grow by nearly 8% year-over-year, reaching $6.38 per share. Following the strong Q3 results and sustained demand for companion animal products, Zoetis has raised its full-year guidance for both revenue and adjusted EPS.

Innovation and Strategic Initiatives

Zoetis remains committed to maintaining its competitive edge through continuous investment in research and development. A notable collaboration includes its partnership with Blacksmith Medicines, Inc. aimed at discovering and developing novel antibiotics for animal health.

Product Pipeline and Recent Developments

- Product Pipeline: In September 2025, Zoetis received a positive opinion from the CVMP for Portela® (relfovetmab), a treatment designed to alleviate pain associated with osteoarthritis in cats.

- Capital Markets: In August 2025, Zoetis announced the pricing of $1.85 billion of senior notes.

Industry Position and Competitive Landscape

Zoetis benefits from several favorable industry trends, including increasing pet ownership globally, growing awareness of animal health importance, and the expanding demand for protein, which drives the need for robust livestock health solutions.

Key competitors in the animal health sector include Elanco Animal Health, Phibro Animal Health, DSM-Firmenich, Prondil, and Abbott India, among others.

The company's strength lies in its diversified portfolio spanning both companion animals and livestock, its extensive global reach, and its strong research and development capabilities. These factors position Zoetis favorably to capitalize on the continually growing global animal health market.